Clinical trials: Meropenem
Pediatric Patients Receiving Venoarterial Extracorporeal Membrane Oxygenation
Population Pharmacokinetics of Vancomycin, Meropenem, Milrinone, Dexmedetomidine and Fentanyl in Pediatric Patients During Extracorporeal Membrane Oxygenation
Extracorporeal membrane oxygenation (ECMO) has been used primarily in newborns since it was first successfully implemented in the 1970s, and has recently increased use in infants and young children.
- Trial name
- NCT04701099
- Where
- South Korea
- Volunteers
- 50 people
- Sponsor
- Yonsei University
Sepsis
Efficacy, Pharmacokinetics and Safety of Meropenem in Infants Below 90 Days With Clinical or Confirmed Late-onset Sepsis
This phase III multicentric international randomized trial is designed to compare the efficacy of Meropenem to the standard of care in infants below 90 days of age with clinical or confirmed late-onset sepsis (LOS).
- Trial name
- NeoMero-1 (NCT01551394)
- Testing
- Meropenem, Ampicillin + gentamicin or cefotaxime + gentamicin
- Where
- Italy
- Volunteers
- 272 people
- Sponsor
- PENTA Foundation
Acute Pyelonephritis, Complicated Urinary Tract Infection
A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Meropenem-Vaborbactam in Children With Complicated Urinary Tract Infection, Including Acute Pyelonephritis
The primary objective of the study is to assess the safety and tolerability of meropenem-vaborbactam administered by intravenous (IV) infusion in children 3 months and above to less than 12 years with complicated urinary tract…
- Trial name
- NCT06672978
- Testing
- Meropenem-Vaborbactam, Antibiotics
- Where
- 26 sites in United States, Bulgaria and 4 more
- Volunteers
- 66 people
- Sponsor
- Rempex (a wholly owned subsidiary of Melinta Therapeutics, LLC)
Complicated Intra-Abdominal Infection
MK-7625A Plus Metronidazole Versus Meropenem in Pediatric Participants With Complicated Intra-Abdominal Infection (cIAI) (MK-7625A-035)
This study aims to evaluate the safety and tolerability of MK-7625A (ceftolozane/tazobactam) plus metronidazole, compared with that of meropenem in pediatric participants with cIAI.
- Trial name
- NCT03217136
- Testing
- Ceftolozane/Tazobactam, Metronidazole, Meropenem
- Where
- 50 sites in United States, Brazil and 10 more
- Volunteers
- 94 people
- Sponsor
- Merck Sharp & Dohme LLC
Abscess, Intra-Abdominal, Abdominal Abscess
A Safety and Tolerability Study of Doripenem Compared With Meropenem in Children Hospitalized With Complicated Intra-abdominal Infections
The purpose of the study is to evaluate the safety and tolerability of doripenem compared with meropenem in children hospitalized with complicated intra-abdominal infections.
- Conditions
- Abscess, Intra-Abdominal, Abdominal Abscess, Abdomen, Acute, Abdominal Pain
- Trial name
- NCT01110382
- Testing
- Doripenem, Meropenem, Amoxicillin/clavulanate potassium
- Where
- 19 sites in United States, Argentina and 6 more
- Volunteers
- 41 people
- Sponsor
- Janssen Research & Development, LLC
Carbapenem Resistant Bacterial Infection, Acinetobacter Bacteremia
Cefiderocol and Ampicillin-sulbactam vs. Colistin +/- Meropenem for Carbapenem Resistant A. Baumannii
Patients with bloodstream infections, hospital acquired pneumonia or ventilator-associated pneumonia caused by carbapenem-resistant Acinetobacter baumannii (CRAB) treated with cefiderocol combined with ampicillin sulbactam will…
- Conditions
- Carbapenem Resistant Bacterial Infection, Acinetobacter Bacteremia, Acinetobacter Pneumonia
- Trial name
- CASCADE (NCT05922124)
- Testing
- Cefiderocol, Ampicillin-sulbactam, Colistin
- Where
- 3 sites in Israel
- Volunteers
- 734 people
- Sponsor
- Rambam Health Care Campus
Pharmacokinetics, Amoxicillin-clavulanate
Pediatric Antibiotic Dosing in Extracorporal Membrane Oxygenation (PADECMO)
Pharmacokinetics of antibiotics in critically ill neonates, infants and children on extracorporeal membrane oxygenation (ECMO).
- Conditions
- Pharmacokinetics, Amoxicillin-clavulanate, Piperacillin-tazobactam, Meropenem
- Trial name
- PADECMO (NCT06426836)
- Testing
- Amoxicillin-clavulanate, Piperacillin-tazobactam, Meropenem
- Where
- 3 sites in Belgium
- Volunteers
- 300 people
- Sponsor
- University Hospital, Ghent
Cystic Fibrosis, Pneumonia
Population Pharmacokinetics of Prolonged Infusion Meropenem in Cystic Fibrosis (CF) Children
This study will determine the concentrations of the antibiotic meropenem when administered as a 3 hour prolonged infusion in children with cystic fibrosis who are hospitalized with an acute pulmonary exacerbation.
- Conditions
- Cystic Fibrosis, Pneumonia, Pseudomonas Aeruginosa Infection
- Trial name
- NCT01429259
- Testing
- meropenem
- Where
- 7 sites in United States
- Volunteers
- 30 people
- Sponsor
- Joseph Kuti
Children；Infection
Population Pharmacokinetics of Meropenem and Linezolid in Children With Severe Infectious Diseases
This study is based on the hypothesis that the pharmacokinetics of meropenem and linezolid in severe infectious children are different from mild infectious children and adults.
- Trial name
- NCT03643497
- Testing
- anti-infective drugs
- Where
- China
- Volunteers
- 800 people
- Sponsor
- Beijing Children's Hospital
Amoxicillin-clavulanate, Piperacillin-tazobactam
Precision Dosing of Beta-lactam Antibiotics in Critically Ill Children
The overall objective of this study is to investigate the impact of early model-informed precision dosing (MIPD) on target attainment of three beta-lactam antibiotics (amoxicillin-clavulanic acid, piperacillin-tazobactam and…
- Conditions
- Amoxicillin-clavulanate, Piperacillin-tazobactam, Meropenem
- Trial name
- MOMENTUM (NCT06929702)
- Testing
- Beta-lactam antibiotic, Beta-lactam model-informed precision dosing
- Where
- Belgium
- Volunteers
- 58 people
- Sponsor
- University Hospital, Ghent
Bacterial Infections
Dose-finding, Pharmacokinetics, and Safety of VABOMERE in Pediatric Subjects With Bacterial Infections
A single dose infusion of Vabomere (meropenem-vaborbactam) is being tested for dose-finding, pharmacokinetics, safety, and tolerability in pediatric subjects from birth to less than 18 years of age with serious bacterial…
- Trial name
- TANGOKIDS (NCT02687906)
- Testing
- Vabomere
- Where
- 9 sites in United States
- Volunteers
- 39 people
- Sponsor
- Rempex (a wholly owned subsidiary of Melinta Therapeutics, LLC)
Complicated Intra-abdominal Infections
Evaluation of Safety,Pharmacokinetics and Efficacy of CAZ-AVI With Metronidazole in Children Aged 3 Months to 18 Years Old With Complicated Intra-abdominal Infections (cIAIs).
This study will assess the safety , efficacy and pharmacokinetics of ceftazidime avibactam and metronidazole versus meropenem in paediatric population (from 3 months to less than 18 years of age )with complicated intra-abdominal…
- Trial name
- NCT02475733
- Testing
- Ceftazidime -avibactam, Meropenem, Metronidazole
- Where
- 35 sites in United States, Czechia and 8 more
- Volunteers
- 83 people
- Sponsor
- Pfizer
Enteric Fever
Meropenem vs Azithromycin Efficacy in Case XDR Enteric Fever
1. Primary Objective: o To evaluate the efficacy of intravenous azithromycin compared with meropenem in the treatment of extensively drug-resistant (XDR) enteric fever. 2.
- Trial name
- NCT07314281
- Testing
- Azithromycin, Meropenem Injection
- Where
- Pakistan
- Volunteers
- 40 people
- Sponsor
- Indus Hospital and Health Network
Gram Negative Organism
Resistance Rates and Mechanisms of Resistance to Imipenem and Meropenem at UPMC
The isolate samples will be collected over a period of one year once IRB approval has been obtained. These isolates were collected as part of the patient's clinical care and once all clinical testing is complete, all isolates…
- Trial name
- NCT00443885
- Where
- 2 sites in United States
- Volunteers
- 500 people
- Sponsor
- University of Pittsburgh
Multi-antibiotic Resistance
Use of New Antibiotics in Sweden
Antibiotic resistance is a growing global health problem of great concern, especially multidrug-resistant Gram-negative bacteria. In recent years some new antibiotics targeting these bacteria have been developed.
- Trial name
- NCT05048693
- Where
- 7 sites in Sweden
- Volunteers
- 41 people
- Sponsor
- Uppsala University
Cystic Fibrosis
Intermittent Versus Continuous Infusion Meropenem in Cystic Fibrosis
The purpose of this study is to compare the incidence of nausea and vomiting following short intermittent versus prolonged intermittent infusion of meropenem.
- Trial name
- NCT02048163
- Where
- United States
- Sponsor
- Dayton Children's Hospital
Pancreatitis
Evaluation of Pancreatic Tissue Penetration of Meronem® in the Prophylaxis of Septic Complications in Severe Pancreatitis
To measure meropenem pancreatic tissue penetration in subjects with severe pancreatitis requiring surgery between 30 to 60 minutes after a bolus of 1 g IV meropenem given during the induction period of anesthesia.
- Trial name
- NCT00318994
- Testing
- Meropenem
- Where
- Colombia
- Volunteers
- 6 people
- Sponsor
- Pfizer
Sepsis, Bacterial Infection
EFFICACY OF PROLONGED INFUSION MEROPENEM IN CRITICALLY ILL PAEDIATRIC INTENSIVE CARE PATIENTS
As a broad-spectrum carbapenem, meropenem is one of the most commonly used antibiotics for critically ill pediatric patients who have severe infections.
- Trial name
- NCT07122596
- Testing
- Meropenem Infusion
- Where
- Pakistan
- Volunteers
- 150 people
- Sponsor
- Pakistan Navy Station Shifa Hospital
Complicated Urinary Tract Infection, Pyelonephritis
MK-7625A Versus Meropenem in Pediatric Participants With Complicated Urinary Tract Infection (cUTI) (MK-7625A-034)
This study aims to evaluate the safety and tolerability of MK-7625A (ceftolozane/tazobactam) compared with that of meropenem in pediatric participants with cUTI, including pyelonephritis.
- Trial name
- NCT03230838
- Testing
- Ceftolozane/Tazobactam, Meropenem
- Where
- 52 sites in United States, Greece and 8 more
- Volunteers
- 134 people
- Sponsor
- Merck Sharp & Dohme LLC
Meningitis
Pharmacokinetics and Safety of Meropenem in Infants Below 90 Days of Age With Probable and Confirmed Meningitis
This phase I-II multicenter international trial is designed to study the pharmacokinetics of meropenem and to characterize the safety profile of meropenem in the treatment of infants ≤ 90 days of postnatal age with probable or…
- Trial name
- NeoMero-2 (NCT01554124)
- Testing
- Meropenem
- Where
- United Kingdom
- Volunteers
- 51 people
- Sponsor
- PENTA Foundation